SHANGHAI, July 9, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central ...
Xenon (XENE) is in the process of nearly completing its phase 3 X-TOLE2 trial using its Kv7 potassium channel opener azetukalner for the treatment of patients with focal onset seizures [FOS]. As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results